Medworxx
Solutions Inc. ("Medworxx") (TSX VENTURE: MWX)
today is pleased to issue a market update for the Medworxx Patient
Throughput Review (“PTR”) program (previously referred to as the Appropriate
Length Stay Audit “ALSA”). Since its introduction in 2013, the PTR
has been widely accepted by hospitals and health systems
internationally. The PTR methodology leverages the Medworxx Clinical
Criteria Module software to unlock unique patient flow information to
help organizations understand the scope of their patient flow issues and
identify specific opportunities to improve quality and performance.
Management consulting companies, Medworxx clinical consultants and
hospital process improvement groups are able to use the Medworxx
Clinical Criteria Module to rapidly identify patient flow data,
providing visibility into patient flow issues in the hospitals that they
provide services to. Consulting companies and hospital process
improvement groups are able to license the Medworxx software to deliver
PTRs independent of Medworxx.
Medworxx customers in the United Kingdom; Royal Liverpool and Broadgreen
University Hospitals NHS Trust and South Tees Hospitals NHS Trust,
completed PTRs before committing to a licensing agreement for the
Medworxx Clinical Criteria Module. These reviews were delivered by
ModelAdvice DC Consulting Ltd. UK, a Medworxx consulting partner. These
two customers now review and assess 1900 beds every day using the
Medworxx Patient Flow Platform.
Since the official launch of the program in June 2013, twenty-five PTRs
have been successfully delivered in five countries; Australia, Canada,
France, the United States and the United Kingdom. Medworxx and their
consulting partners are working with each site to analyze PTR data to
support strategic decision making and improve performance and quality
outcomes.
“We are excited to see PTR adoption not just in Canada but in
international markets as well. This further validates that the value of
our patient flow offering is not just isolated to Canada and confirms
our ability to expand into international markets. We have now seen the
PTR perform in hospitals across five countries; these sites have a
combined total of approximately 23,000 acute care beds. The Patient
Throughput Review presents an opportunity for Medworxx to expand the use
of our embedded operational patient flow solution to all of our PTR
clients,” said Dan Matlow, CEO and President, Medworxx.
About Medworxx
Medworxx delivers health information technology solutions to over 350
hospitals internationally. Medworxx helps hospitals meet patient flow
challenges, and requirements in compliance and education. Medworxx
Clinical Criteria – flagship of Medworxx Patient Flow that includes
electronic bed board and independent assessment components – currently
serves 34% of the acute care beds in Canada. Founded in 2004, Medworxx
is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.
For more information visit: http://www.medworxx.com.
Disclaimer
The statements made in this press release may contain forward-looking
statements that may involve a number of risks and uncertainties. Actual
events or results could differ materially from the company’s
expectations and projections. The TSX Venture Exchange has not reviewed
this press release and neither approved nor disapproved the information
contained in this press release.
Copyright Business Wire 2014